Top Abstract Purchase Related
Home
>
Node
>
Subnode

Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections

Peppard, W.J.; Schuenke, C.D.

Current Opinion in Investigational Drugs 9(2): 210-225

2008

ISSN/ISBN: 1472-4472
PMID: 18246524
Document Number: 616961
Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the potential treatment of methicillin-resistant Staphylococcus aureus infections, including complicated skin and skin structure infections and hospital-acquired pneumonia. Phase III cSSSI clinical trials have been completed and an NDA filing process is ongoing. A phase II clinical trial for hospital-acquired pneumonia is ongoing.

Document emailed within 1 workday
Secure & encrypted payments

Cheng, Y.C.; Dutschman, G.E.; Starnes, M.C.; Fisher, M.H.; Nanavathi, N.T.; Nair, M.G. 1985: Activity of the new antifolate N10-propargyl-5,8-dideazafolate and its polyglutamates against human dihydrofolate reductase, human thymidylate synthetase, and KB cells containing different levels of dihydrofolate reductase Cancer Research 45(2): 598-600
Peterson, D.S.; Di Santi, S.M.; Povoa, M.; Calvosa, V.S.; Do Rosario, V.E.; Wellems, T.E. 1991: Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon American Journal of Tropical Medicine and Hygiene 45(4): 492-497
Danchaivijitr, S.; Trakulsomboon, S. 1989: Patients colonized by antibiotic resistant bacteria--a potential source of infections in the medical wards Journal of the Medical Association of Thailand 72(Suppl 2): 33-38
Giannoukakis, N. 2006: Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications Current Opinion in Investigational Drugs 7(10): 916-923
Kotyla, P.J.; Sliwinska-Kotyla, B.; Kucharz, E.J. 2006: Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin Journal of rheumatology 33(11): 2361-3; author reply 2363
Padeĭskaia, E.N. 1989: A new drug sulfaton in the combined treatment of infections with sulfanilamide derivatives and diaminopyrimidine Antibiotiki i Khimioterapiia 34(9): 657-662
Bertoye, A.; Gaillard, L.; Courtieu, A.L. 1959: Adapted bacteriophages in the treatment of infections caused by antibiotic-resistant microorganisms Journal de Medecine de Lyon 40(945): 465-471
Mcewen, W.W. 1964: Adjuvant to Antibiotic Therapy in Staphylococcal Infections. a Preliminary Investigation Journal of the Medical Society of New Jersey 61: 221-225
Onicescu, D.; Taşcă, L. 1977: A possible histochemical mechanism of dihydrofolate reductase reaction Morphologie et Embryologie 23(2): 103-106
Bowden, K.; Harris, N.V.; Watson, C.A. 1993: Structure-activity relationships of dihydrofolate reductase inhibitors Journal of ChemoTherapy 5(6): 377-388
Azizkhan, J.C.; Jensen, D.E.; Pierce, A.J.; Wade, M. 1993: Transcription from TATA-less promoters: dihydrofolate reductase as a model Critical Reviews in Eukaryotic Gene Expression 3(4): 229-254
Dellamonica, P.; Mondain, V.; Bernard, E.; Brun, Y.; Etesse, H.; Barbarin, A.; Sicard, D. 1984: Evaluation of the use of rifampin combinations in severe staphylococcal infections. Apropos of the selection of 7 resistant mutants Pathologie-Biologie 32(5 Pt 2): 559-562
Hartman, P.G. 1993: Molecular aspects and mechanism of action of dihydrofolate reductase inhibitors Journal of Chemotherapy 5(6): 369-376
Ercikan-Abali, E.A.; Mineishi, S.; Tong, Y.; Nakahara, S.; Waltham, M.C.; Banerjee, D.; Chen, W.; Sadelain, M.; Bertino, J.R. 1996: Active site-directed double mutants of dihydrofolate reductase Cancer Research 56(18): 4142-4145
Nano, R.; Gerzeli, G.; Spadari, S. 1991: Modulation of cytochemically detected dihydrofolate reductase during cell cycle Cellular and Molecular Biology 37(8): 831-837
Schalhorn, A.; Wilmanns, W. 1979: Inhibition of human leukocytes dihydrofolate reductase by triamterene and its metabolites Arzneimittel-Forschung 29(9): 1409-1411
Kawai, M.; Hillcoat, B.L. 1974: Interaction of thymidylate synthetase and dihydrofolate reductase enzymes in vitro and in vivo Cancer Research 34(7): 1619-1626
Volm, M.; Sauerbrey, A.; Zintl, F. 1994: Dihydrofolate-reductase and thymidylate-synthase in childhood acute lymphoblastic leukemia Anticancer Research 14(3b): 1377-1381
Fogel, G.B.; Cheung, M.; Pittman, E.; Hecht, D. 2008: In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase Journal of Molecular Graphics and Modelling 26(7): 1145-1152
Hata, K.; Kono, R.; Fujisawa, M.; Kitahara, R.; Kamatari, Y.O.; Akasaka, K.; Xu, Y. 2004: High pressure nmr study of dihydrofolate reductase from a deep-sea bacterium Moritella profunda Cellular and Molecular Biology 50(4): 311-316